FDA Dumps Rigid Methods Rule to Streamline Enforcement Testing
Published Date: 2/19/2026
Rule
Summary
The FDA is officially scrapping a rule that told them which testing methods to use when no specific method was required by law. This change affects anyone involved in FDA enforcement programs but won’t cost extra or cause delays. The new rule kicks in on March 23, 2026, making things simpler and more flexible for everyone.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Validation and accreditation remain required
FDA states the revocation does not permit use of unvalidated methods and that methods used by FDA will continue to undergo qualification, validation, and fitness-for-use, including under ISO/IEC 17025 accreditation frameworks and the Laboratory Accreditation for Analyses of Foods (LAAF) program where applicable.
FDA drops AOAC default rule
The FDA removed 21 CFR 2.19, which said the Agency would default to AOAC (13th Ed., 1980) methods in enforcement programs when no method is specified by law. The revocation becomes effective March 23, 2026 and means FDA is no longer required to use that single compendium as its default.
No monetized costs or savings
FDA estimates the final rule will produce $0 in annualized monetized costs and $0 in monetized benefits (at both 3% and 7% discount rates, annualized over 10 years). The Agency also certified the rule will not have a significant economic impact on a substantial number of small entities.
FDA will list preferred methods in guidance
Instead of relying on a single incorporated compendium, FDA will identify preferred and validated analytical methods in documents that can be updated more frequently (for example, Agency methods compendia, compliance program guidance, and other resources). This is intended to allow more flexibility and quicker updates as science advances.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03284 — Amendment of Class D, Class E2, Class E4 and Class E5 Airspace Over Patuxent River, MD
The FAA is updating the airspace rules around Patuxent River Naval Air Station in Maryland to better cover all flight operations and remove outdated navigation references. These changes affect pilots flying under instrument flight rules and take effect on May 14, 2026. No new fees or costs are involved—just clearer, safer skies!
Next: 2026-03286 — Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and the European Community
Starting March 23, 2026, the FDA is canceling old rules that let the U.S. and European Union share certain drug and medical device inspection reports. These rules are outdated because a newer agreement from 2017 already covers this sharing. Companies making medicines and medical devices in both places should note this change, but it won’t add extra costs or delays.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in